Pre-made Enapotamab benchmark antibody ( Whole mAb ADC, anti-AXL therapeutic antibody, Anti-ARK/UFO/JTK11/Tyro7 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Enapotamab biosimilar, Whole mAb ADC, Anti-AXL Antibody: Anti-ARK/UFO/JTK11/Tyro7 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Enapotamab vedotin (HuMax®-AXL-ADC) is an antibody-drug conjugate (ADC) targeted to Axl (from anexelekto, or uncontrolled growth). Axl is a unique RTK that is aberrantly expressed in many solid tumor types and is implicated in tumor cell proliferation, migration, and invasion.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-179-1mg	1mg	4635
GMP-Bios-ab-179-10mg	10mg	Inquiry
GMP-Bios-ab-179-100mg	100mg	Inquiry
GMP-Bios-ab-179-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Enapotamab biosimilar, Whole mAb ADC, Anti-AXL Antibody: Anti-ARK/UFO/JTK11/Tyro7 therapeutic antibody
INN Name	Enapotamab
Target	AXL
Format	Whole mAb ADC
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2017
Year Recommended	2018
Companies	Genmab
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Solid tumours
Development Tech	na